Document:

exv10w6

 

Exhibit 10.6

PERSONAL AND CONFIDENTIAL

November 6, 2007

Dear                     :

The Compensation and Benefits Committee of the Anadarko Board of Directors has made an award of
performance units (“PUs”) to you under the Company’s 1999 Stock Incentive Plan, as may be amended
from time to time (the “Plan”). The PUs are subject to all terms and conditions of the Plan, the
summary (prospectus) of the Plan and the provisions of this grant letter. The Plan summary is
available via the Anadarko intranet at the following address:
http://insider.anadarko.com/hr/stock_plan/1999_Restated_SIP_SPD_01-01-05.pdf.

You have been awarded {Target} PUs as your target. The vesting of these units is dependent upon the
Company’s relative Total Shareholder Return (“TSR”) over the specified Performance Periods. Fifty
percent (50%) of the target PUs are subject to a two year Performance Period that begins 1/1/2008
and ends 12/31/2009 (the “2009 Performance Period”) and 50% of the target PUs are subject to a
three year Performance Period that begins 1/1/2008 and ends 12/31/2010 (the “2010 Performance
Period”). The 2009 and 2010 Performance Period may each be individually referred to herein as a
“Performance Period”. The maximum number of PUs that you can earn during each Performance Period
will be calculated as follows {Target x 50% x 200%}, with actual payout based on the Company’s
relative TSR ranking as described below.

Each PU represents the value of one share of the Company’s common stock. The payout of PUs is
contingent upon the Company’s TSR ranking relative to a predetermined peer group during a
Performance Period. The TSR measure provides an external comparison of the Company’s performance
against a peer group of companies and will be calculated as follows:

Average Closing Stock Price for the last 30 trading days of the Performance Period

Minus

Average Closing Stock Price for the 30 trading days preceding the beginning of the Performance

Period

Plus

Dividends paid per share over the Performance Period

Total Above Divided By

Average Closing Stock Price for the 30 trading days preceding the beginning of the Performance

Period

The actual number of PUs you will earn for each Performance Period is based upon the Company’s
relative TSR ranking as follows:

1

 

	 	 	 	 	 
	Anadarko	 	 	 	Payout
	Relative	 	Percentile	 	as % of
	Ranking	 	Rank	 	Target
	1st
	 	100%
	 	200%
	2nd
	 	91%
	 	182%
	3rd
	 	82%
	 	164%
	4th
	 	73%
	 	146%
	5th
	 	64%
	 	128%
	6th
	 	55%
	 	110%
	7th
	 	46%
	 	92%
	8th
	 	36%
	 	72%
	9th
	 	27%
	 	54%
	10th
	 	18%
	 	0%
	11th
	 	9%
	 	0%
	12th
	 	0%
	 	0%

For example, if you were awarded 1,000 target PUs and the Company’s relative ranking for the 2009
Performance Period is 3rd, you will receive 820 PUs (1,000 x 50% x 164%) at the end of
the 2009 Performance Period (subject to the other terms and conditions of this grant letter). If
the Company’s relative ranking for the 2010 Performance Period is 1st, you will receive
1,000 PUs (1000 x 50% x 200%) at the end of the 2010 Performance Period (subject to the other terms
and conditions of this grant letter).

The peer group for the 2009 Performance Period and the 2010 Performance Period include Apache
Corporation, ConocoPhillips, Devon Energy Corporation, EnCana Corporation, EOG Resources Inc., Hess
Corporation, Marathon Oil Corporation, Noble Energy Inc., Occidental Petroleum Corporation, Pioneer
Natural Resources Company and Talisman Energy Inc. If any peer companies cease to exist during
either of the Performance Periods, the Compensation Committee has approved Chevron Corporation,
Chesapeake Energy Corporation and XTO Energy, Inc. as replacement companies (in the order
provided).

At the end of each Performance Period, the value attributed to the PUs that vest on such date shall
be reduced by the applicable payroll taxes as a result of such vesting, and the resulting amount
shall then be converted into shares of unrestricted Anadarko common stock using the closing price
of the Company’s common stock on the last day of the Performance Period. Your shares will be
deposited in a direct registration account at Mellon.

Dividend Equivalents shall not be paid with respect to the PUs. The PUs do not have voting rights.
PUs do, however, count toward your stock ownership requirements.

You will be allowed to make an election to defer your entire PU award. All deferral elections and
distributions must be made in compliance with 409A regulations and made on a separate form provided
by Anadarko to you.

If you voluntarily terminate your employment, or in the event you are terminated for cause, all
unvested PUs will be immediately forfeited. Upon your death, disability (as defined in the
Company’s disability plan), involuntary termination without cause or a change in control event (as
defined in the Plan) all your unvested PUs will be paid to you in accordance with your

2

 

Target.
Upon your retirement (as defined by the applicable Company Retirement Plan) prior to the end of a
Performance Period, you will receive a prorated payout, paid after the end of the Performance
Period, based on actual performance and the number of months you worked. Your PUs are subject to
several restrictions, including that such PUs may not be transferred, sold, assigned, pledged,
exchanged, hypothecated or otherwise transferred, or disposed of to the extent then subject to
restrictions.

Once PUs have vested and shares of Anadarko common stock have been delivered to you, you are free
to sell, gift or otherwise dispose of such shares; provided that you comply with the applicable
restrictions under the Company’s Insider Trading Policy (including the receipt of pre-clearance)
and the applicable stock ownership requirements.

If you have any questions on this grant, please call Preston Johnson at 832-636-2705.

Sincerely,

 

 

 

3exv4w1

 

EXHIBIT 4.1

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW, AND MAY NOT
BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF OR EXERCISED UNLESS
(i) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS SHALL
HAVE BECOME EFFECTIVE WITH REGARD THERETO, OR (ii) AN EXEMPTION FROM REGISTRATION UNDER THE
SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS IS AVAILABLE IN CONNECTION WITH SUCH OFFER,
SALE OR TRANSFER.

AN INVESTMENT IN THESE SECURITIES INVOLVES A HIGH DEGREE OF RISK. HOLDERS MUST RELY ON THEIR OWN
ANALYSIS OF THE INVESTMENT AND ASSESSMENT OF THE RISKS INVOLVED.

     Warrant to Purchase

			
	           shares
	 	Warrant Number                     

Warrant to Purchase Common Stock

of

MIDDLEBROOK PHARMACEUTICALS, INC.

THIS CERTIFIES that [NAME OF PURCHASER] or any subsequent holder hereof (“Holder”) has the right to
purchase from MIDDLEBROOK PHARMACEUTICALS, INC., a Delaware corporation, (the “Company”),      
(     ) fully paid and nonassessable shares, of the Company’s common stock, $0.01 par
value per share (“Common Stock”), subject to adjustment as provided herein, at a price equal to the
Exercise Price as defined in Section 3 below, at any time during the Term (as defined below).

Holder agrees with the Company that this Warrant to Purchase Common Stock of the Company (this
“Warrant” or this “Agreement”) is issued and all rights hereunder shall be held subject to all of
the conditions, limitations and provisions set forth herein.

1. Date of Issuance and Term.

This Warrant shall be deemed to be issued on November                     , 2007 (“Date of Issuance”). The term of
this Warrant begins on the Date of Issuance and ends at 5:00 p.m., New York City time, on the date
that is six (6) years after the Date of Issuance (the “Term”). This Warrant was issued in
conjunction with that certain Asset Purchase Agreement (the “Purchase Agreement”) and the
Registration Rights Agreement (“Registration Rights Agreement”) by and between the Company,
Deerfield Special Situations Fund, L.P. and certain other parties, each dated November                     , 2007,
entered into in conjunction herewith.

Notwithstanding anything herein to the contrary, the Company shall not issue to the Holder, and the
Holder may not acquire, a number of shares of Common Stock upon exercise of this Warrant to the
extent that, upon such exercise, the number of shares of Common Stock then beneficially owned by
the Holder and its Affiliates and any other persons or entities whose beneficial ownership of
Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Securities
Exchange Act of 1934 (the “Exchange Act”) (including shares held by any “group” of which the Holder
is a member, but excluding shares beneficially owned by virtue of the ownership of securities or
rights to acquire securities that have limitations on the right to convert, exercise or purchase
similar to the limitation set forth herein) would exceed 9.98% of the total number of shares of
Common Stock of the Company then issued and outstanding. For purposes hereof, “group” has the
meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the Securities
and Exchange Commission (the “SEC”), and the percentage held by the Holder shall be determined in a
manner consistent with the provisions of Section 13(d) of the Exchange Act. Upon the written
request of the Holder, the Company shall, within two (2) Trading Days confirm orally and in writing
to the Holder the number of shares of Common Stock then outstanding.

“Affiliate” means any person or entity that, directly or indirectly through one or more
intermediaries, controls or is controlled by or is under common control with a person or entity, as
such terms are used in and construed under Rule 144 under the Securities Act of 1933, as amended
(the “Securities Act”). With respect to a Holder of Warrants, any investment fund or managed
account that is managed on a discretionary basis by the same investment manager as such Holder will
be deemed to be an Affiliate of such Holder.

“Holder” means [Name of Purchaser] and any transferee or assignee pursuant to the terms of this
Warrant.

2. Exercise.

(a) Manner of Exercise. During the Term, this Warrant may be Exercised as to all or any lesser
number of full shares of Common Stock covered hereby (the “Warrant Shares” or the “Shares”) upon
surrender of this Warrant, with the Exercise Form attached hereto as Exhibit A (the
“Exercise Form”) duly completed and executed, together with the full Exercise Price (as defined
below, which may

 

 

be satisfied by a Cash Exercise or a Cashless Exercise, as each is defined below) for each share of
Common Stock as to which this Warrant is Exercised, at the office of the Company, MiddleBrook
Pharmaceuticals, Inc., 20425 Seneca Meadows Parkway; Germantown, MD 20876; Phone: (301) 944-6600,
Fax: (301) 944-6700, or at such other office or agency as the Company may designate in writing, by
overnight mail, with an advance copy of the Exercise Form sent to the Company and its transfer
agent (“Transfer Agent”) by facsimile (such surrender and payment of the Exercise Price hereinafter
called the “Exercise” of this Warrant).

(b) Date of Exercise. The “Date of Exercise” of the Warrant shall be defined as the date that the
Exercise Form attached hereto as Exhibit A, completed and executed, is sent by facsimile to
the Company, provided that the original Warrant and Exercise Form are received by the Company and
the Exercise Price is satisfied, each as soon as practicable thereafter. Alternatively, the Date of
Exercise shall be defined as the date the original Exercise Form is received by the Company, if
Holder has not sent advance notice by facsimile. Upon delivery of the Exercise Form to the Company
by facsimile or otherwise, the Holder shall be deemed for all corporate purposes to have become the
holder of record of the Warrant Shares with respect to which this Warrant has been Exercised,
irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or the date
of delivery of the certificates evidencing such Warrant Shares as the case may be.

(c) Delivery of Common Stock Upon Exercise. Within three (3) business days after any Date of
Exercise (the “Delivery Period”), the Company shall issue and deliver (or cause its Transfer Agent
so to issue and deliver) in accordance with the terms hereof to or upon the order of the Holder
that number of shares of Common Stock (“Exercise Shares”) for the portion of this Warrant converted
as shall be determined in accordance herewith. Upon the Exercise of this Warrant or any part
thereof, the Company shall, at its own cost and expense, take all necessary action, including
obtaining and delivering, an opinion of counsel to assure that the Transfer Agent shall issue stock
certificates in the name of Holder (or its nominee) or such other persons as designated by Holder
and in such denominations to be specified at Exercise representing the number of shares of Common
Stock issuable upon such Exercise. The Company warrants that no instructions other than these
instructions have been or will be given to the Transfer Agent and that, unless waived by the
Holder, this Warrant and the Exercise Shares will be free-trading, and freely transferable, and
will not contain a legend restricting the resale or transferability of the Exercise Shares if the
Unrestricted Conditions (as defined below) are met.

(d) Delivery Failure. In addition to any other remedies which may be available to the Holder, in
the event that the Company fails to use its best efforts to effect delivery of the Exercise Shares
by the end of the Delivery Period (a “Delivery Failure”), the Holder will be entitled prior to the
delivery of the Shares to revoke all or part of the relevant Exercise Form by delivery of a notice
to such effect to the Company whereupon the Company and the Holder shall each be restored to their
respective positions immediately prior to the delivery of such notice, except that the liquidated
damages described herein shall be payable through the date notice of revocation or rescission is
given to the Company.

(e) Legends.

(i) Restrictive Legend. The Holder understands that until such time as this Warrant and the
Exercise Shares have been registered under the Securities Act as contemplated by the Registration
Rights Agreement or otherwise may be sold pursuant to Rule 144 or Rule 144(k) under the Securities
Act or an exemption from registration under the Securities Act without any restriction as to the
number of securities as of a particular date that can then be immediately sold, this Warrant and
the Exercise Shares may bear a restrictive legend in substantially the following form (and a
stop-transfer order may be placed against transfer of the certificates for such securities):

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES
MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION
UNDER SAID ACT INCLUDING, WITHOUT LIMITATION, PURSUANT TO RULES 144 OR 144A UNDER SAID ACT
OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC
INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4(1) AND A HALF” SALE.”

“THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE
SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN REGISTRATION RIGHTS AGREEMENT DATED AS OF
NOVEMBER                     _, 2007, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND A CERTAIN HOLDER OF
ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN
REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.”

(ii) Removal of Restrictive Legends. This Warrant and certificates evidencing the Exercise
Shares shall not contain any legend restricting the transfer thereof (including the legend set
forth above in subsection 2(e)(i)): (A) while a registration statement (including a Registration
Statement, as defined in the Registration Rights Agreement) covering the sale or resale of such
security is effective under the Securities Act, or (B) following any sale of such Warrant and/or
Exercise Shares pursuant to Rule 144, or (C) if such Warrant and/or Exercise Shares are eligible
for sale under Rule 144(k), or (D) if such legend is not required under applicable requirements of
the Securities Act (including judicial interpretations and pronouncements issued by the staff of
the SEC) (collectively, the “Unrestricted Conditions”). The Company shall cause its counsel to
issue a legal opinion to the Transfer Agent promptly after the Effective Date if required by the
Company’s transfer agent to effect the issuance of this Warrant and Exercise Shares without a

 

 

restrictive legend or removal of the legend hereunder. If the Unrestricted Conditions are met at
the time of issuance of this Warrant and/or Exercise Shares, then such Warrant and/or Exercise
Shares shall be issued free of all legends. The Company agrees that following the Effective Date or
at such time as the Unrestricted Conditions are met or such legend is otherwise no longer required
under this Section 2(e), it will, no later than three (3) Trading Days following the delivery (the
“Unlegended Shares Delivery Deadline”) by the Holder to the Company or the Transfer Agent of this
Warrant and a certificate representing Exercise Shares, as applicable, issued with a restrictive
legend (such third Trading Day, the “Legend Removal Date”), deliver or cause to be delivered to
such Holder this Warrant and/or a certificate (or electronic transfer) representing such shares
that is free from all restrictive and other legends. For purposes hereof, “Effective Date” shall
mean the date that the Registration Statement that the Company is required to file pursuant to the
Registration Rights Agreement has been declared effective by the SEC.

(iii) Sale of Unlegended Shares. Holder agrees that the removal of the restrictive legend
from this Warrant and any certificates representing securities as set forth in this Section 2(e)(i)
above is predicated upon the Company’s reliance that the Holder will sell this Warrant and/or any
Exercise Shares pursuant to either the registration requirements of the Securities Act, including
any applicable prospectus delivery requirements, or an exemption therefrom, and that if such
securities are sold pursuant to a Registration Statement, they will be sold in compliance with the
plan of distribution set forth therein.

(f) Cancellation of Warrant. This Warrant shall be canceled upon the full Exercise of this Warrant,
and, as soon as practical after the Date of Exercise, Holder shall be entitled to receive Common
Stock for the number of shares purchased upon such Exercise of this Warrant, and if this Warrant is
not Exercised in full, Holder shall be entitled to receive a new Warrant (containing terms
identical to this Warrant) representing any unexercised portion of this Warrant in addition to such
Common Stock.

(g) Holder of Record. Each person in whose name any Warrant for shares of Common Stock is issued
shall, for all purposes, be deemed to be the Holder of record of such shares on the Date of
Exercise of this Warrant, irrespective of the date of delivery of the Common Stock purchased upon
the Exercise of this Warrant. Nothing in this Warrant shall be construed as conferring upon Holder
any rights as a stockholder of the Company.

(h) Delivery of Electronic Shares. In lieu of delivering physical certificates representing the
Common Stock issuable upon Exercise or legend removal, provided the Company’s Transfer Agent is
participating in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer (“FAST”)
program, upon written request of the Holder, the Company shall use its best efforts to cause its
Transfer Agent to electronically transmit the Common Stock issuable upon Exercise to the Holder by
crediting the account of the Holder’s prime broker with DTC through its Deposit Withdrawal Agent
Commission (DWAC) system. The time periods for delivery and penalties described herein shall apply
to the electronic transmittals described herein. Any delivery not effected by electronic
transmission shall be effected by delivery of physical certificates.

(i) Buy-In. In addition to any other rights available to the Holder, if the Company fails to cause
its Transfer Agent to transmit to the Holder a certificate or certificates representing the
Exercise Shares pursuant to an Exercise on or before the Delivery Period, and if after such date
the Holder is required by its broker to purchase (in an open market transaction or otherwise) or
the Holder’s brokerage firm otherwise purchases shares of Common Stock to deliver in satisfaction
of a sale by the Holder of the Exercise Shares which the Holder anticipated receiving upon such
Exercise (a “Buy-In”), then the Company shall (1) pay in cash to the Holder the amount by which (x)
the Holder’s total purchase price (including brokerage commissions, if any) for the shares of
Common Stock so purchased exceeds (y) the amount obtained by multiplying (A) the number of Exercise
Shares that the Company was required to deliver to the Holder in connection with the Exercise at
issue by (B) the price at which the sell order giving rise to such purchase obligation was
executed, and (2) at the option of the Holder, either reinstate the portion of the Warrant and
equivalent number of Exercise Shares for which such Exercise was not honored or deliver to the
Holder the number of shares of Common Stock that would have been issued had the Company timely
complied with its Exercise and delivery obligations hereunder. For example, if the Holder purchases
Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an
attempted Exercise to cover the sale of Common Stock with an aggregate sale price giving rise to
such purchase obligation of $10,000, under clause (1) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written
notice indicating the amounts payable to the Holder in respect of the Buy-In, together with
applicable confirmations and other evidence reasonably requested by the Company. Nothing herein
shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in
equity including, without limitation, a decree of specific performance and/or injunctive relief
with respect to the Company’s failure to timely deliver certificates representing shares of Common
Stock upon Exercise of the Warrant as required pursuant to the terms hereof.

3. Payment of Warrant Exercise Price.

(a) Exercise Price. The Exercise Price (“Exercise Price”) shall initially equal
$      per share subject to adjustment pursuant to the terms hereof, including but not limited to
Section 5 below.

Payment of the Exercise Price may be made by either of the following, or a combination thereof, at
the election of Holder:

(i) Cash Exercise: The Holder may exercise this Warrant in cash, bank or cashier’s check or wire
transfer (a “Cash Exercise”); or

 

 

(ii) Cashless Exercise: The Holder, at its option, may exercise this Warrant in a cashless exercise
transaction. In order to effect a Cashless Exercise, the Holder shall surrender this Warrant at the
principal office of the Company together with notice of cashless election, in which event the
Company shall issue Holder a number of shares of Common Stock computed using the following formula
(a “Cashless Exercise”):

X = Y (A-B)/A

where: X = the number of shares of Common Stock to be issued to Holder.

Y = the number of shares of Common Stock for which this Warrant is being Exercised.

A = the Market Price of one (1) share of Common Stock (for purposes of this Section 3(ii),
where “Market Price,” as of any date, means the Volume Weighted Average Price (as defined
herein) of the Company’s Common Stock during the ten (10) consecutive Trading Day period
immediately preceding the date in question.

B = the Exercise Price.

As used herein, the “Volume Weighted Average Price” for any security as of any date means the
volume weighted average sale price on The NASDAQ Global Market (“NASDAQ”) as reported by, or
based upon data reported by, Bloomberg Financial Markets or an equivalent, reliable reporting
service mutually acceptable to and hereafter designated by holders of a majority in interest of
the Warrants and the Company (“Bloomberg”) or, if NASDAQ is not the principal trading market
for such security, the volume weighted average sale price of such security on the principal
securities exchange or trading market where such security is listed or traded as reported by
Bloomberg, or, if no volume weighted average sale price is reported for such security, then the
last closing trade price of such security as reported by Bloomberg, or, if no last closing
trade price is reported for such security by Bloomberg, the average of the bid prices of any
market makers for such security that are listed in the over the counter market by the National
Association of Securities Dealers or in the “pink sheets” by the National Quotation Bureau,
Inc. If the Volume Weighted Average Price cannot be calculated for such security on such date
in the manner provided above, the volume weighted average price shall be the fair market value
as mutually determined by the Company and the Holders of a majority in interest of the Warrants
being Exercised for which the calculation of the volume weighted average price is required in
order to determine the Exercise Price of such Warrants. “Trading Day” shall mean any day on
which the Common Sock is traded for any period on NASDAQ, or on the principal securities
exchange or other securities market on which the Common Stock is then being traded.

For purposes of Rule 144 and sub-section (d)(3)(ii) thereof, it is intended, understood and
acknowledged that the Common Stock issuable upon Exercise of this Warrant in a cashless Exercise
transaction shall be deemed to have been acquired at the time this Warrant was issued. Moreover, it
is intended, understood and acknowledged that the holding period for the Common Stock issuable upon
Exercise of this Warrant in a cashless Exercise transaction shall be deemed to have commenced on
the date this Warrant was issued.

(b) Dispute Resolution. In the case of a dispute as to the determination of the closing price or
the Volume Weighted Average Price of the Company’s Common Stock or the arithmetic calculation of
the Exercise Price, Market Price or any Major Transaction Warrant Redemption Price, the Company
shall submit the disputed determinations or arithmetic calculations via facsimile within two (2)
business days of receipt, or deemed receipt, of the Exercise Notice or Redemption Notice, or other
event giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company
are unable to agree upon such determination or calculation within two (2) business days of such
disputed determination or arithmetic calculation being submitted to the Holder, then the Company
shall, within two (2) business days submit via facsimile (i) the disputed determination of the
closing price or the Volume Weighted Average Price of the Company’s Common Stock to an independent,
reputable investment bank selected by the Company and approved by the Holder, which approval shall
not be unreasonably withheld or (ii) the disputed arithmetic calculation of the Exercise Price,
Market Price or any Major Transaction Warrant Redemption Price to the Company’s independent,
outside accountant. The Company, at the Company’s expense, shall cause the investment bank or the
accountant, as the case may be, to perform the determinations or calculations and notify the
Company and the Holder of the results no later than five (5) business days from the time it
receives the disputed determinations or calculations. Such investment bank’s or accountant’s
determination or calculation, as the case may be, shall be binding upon all parties absent
demonstrable error.

4. Transfer and Registration.

(a) Transfer Rights. Subject to the provisions of Section 8 of this Warrant, this Warrant may be
transferred on the books of the Company, in whole or in part, in person or by attorney, upon
surrender of this Warrant properly completed and endorsed. This Warrant shall be canceled upon such
surrender and, as soon as practicable thereafter, the person to whom such transfer is made shall be
entitled to receive a new Warrant or Warrants as to the portion of this Warrant transferred, and
Holder shall be entitled to receive a new Warrant as to the portion hereof retained.

(b) Registrable Securities. This Warrant and the Common Stock issuable upon the Exercise of this
Warrant have registration rights pursuant to the Registration Rights Agreement.

 

 

5. Anti-Dilution Adjustments; Additional Adjustments; Purchase Rights.

(a) Participation. The Holder, as the holder of this Warrant, shall be entitled to receive such
dividends paid and distributions of any kind made to the holders of Common Stock of the Company to
the same extent as if the Holder had Exercised this Warrant into Common Stock (without regard to
any limitations on exercise herein or elsewhere and without regard to whether or not a sufficient
number of shares are authorized and reserved to effect any such exercise and issuance) and had held
such shares of Common Stock on the record date for such dividends and distributions. Payments under
the preceding sentence shall be made concurrently with the dividend or distribution to the holders
of Common Stock.

(b) Recapitalization or Reclassification. If the Company shall at any time effect a
recapitalization, reclassification or other similar transaction of such character that the shares
of Common Stock shall be changed into or become exchangeable for a larger or smaller number of
shares, then upon the effective date thereof, the number of shares of Common Stock which Holder
shall be entitled to purchase upon Exercise of this Warrant shall be increased or decreased, as the
case may be, in direct proportion to the increase or decrease in the number of shares of Common
Stock by reason of such recapitalization, reclassification or similar transaction, and the Exercise
Price shall be, in the case of an increase in the number of shares, proportionally decreased and,
in the case of decrease in the number of shares, proportionally increased. The Company shall give
Holder the same notice it provides to holders of Common Stock of any transaction described in this
Section 5(b).

(c) Rights Upon Major Transaction.

(i) Major Transaction. In the event that a Major Transaction (as defined below) occurs, the Holder,
at its option, may require the Company to redeem the Holder’s outstanding Warrants in accordance
with Section 5(c)(iii) below. Otherwise, a Major Transaction shall be treated as an Assumption (as
defined below) in accordance with Section 5(c)(ii) below unless the Holder waives its rights under
this Section 5(c) with respect to that Major Transaction. Each of the following events shall
constitute a “Major Transaction”:

(A) a consolidation, merger, exchange of shares, recapitalization, reorganization, business
combination or other similar event, (1) following which the holders of Common Stock immediately
preceding such consolidation, merger, exchange, recapitalization, reorganization, combination or
event either (a) no longer hold a majority of the shares of Common Stock or (b) no longer have the
ability to elect a majority of the board of directors of the Company or (2) as a result of which
shares of Common Stock shall be changed into (or the shares of Common Stock become entitled to
receive) the same or a different number of shares of the same or another class or classes of stock
or securities of the Company or another entity (collectively, a “Change of Control Transaction”);

(B) the sale or transfer of significant assets of the Company which, without limitation, shall
include, but not be limited to, a sale or transfer of assets in one transaction or a series of
related transactions for a purchase price of more than $25,000,000, a sale or transfer of more than
60% of the Company’s assets or a sale or transfer of assets or proprietary rights that are material
to the operations and business of the Company;

(C) a purchase, tender or exchange offer made to the holders of outstanding shares of Common Stock,
such that following such purchase, tender or exchange offer a Change of Control Transaction shall
have occurred;

(D) an issuance or series of issuances by the Company after the date of this Warrant, without the
Approval of the Holder, of an aggregate number of shares of Common Stock in excess of 25% of the
Company’s outstanding Common Stock as of the date hereof;

(E) ) the liquidation, bankruptcy, insolvency, dissolution or winding-up (or the occurrence of any
analogous proceeding) affecting the Company; or

(F) the shares of Common Stock cease to be listed, traded or publicly quoted on the NASDAQ Global
Market and are not promptly re-listed or requoted on either the New York Stock Exchange, the
American Stock Exchange, the NASDAQ Global Select Market or the NASDAQ Capital Market.

(ii) Assumption. The Company shall not enter into a Major Transaction unless (i) any Person
purchasing the Company’s assets or Common Stock, or any successor entity resulting from such Major
Transaction (in each case, a “Successor Entity”), assumes in writing all of the obligations of the
Company under this Warrant, the Purchase Agreement and the Registration Rights Agreement in
accordance with the provisions of this Section 5(c)(ii) pursuant to written agreements in form and
substance satisfactory to the Holder and approved by the Holder prior to such Major Transaction,
including agreements to deliver to each holder of Warrants in exchange for such Warrants a security
of the Successor Entity evidenced by a written instrument substantially similar in form and
substance to the Warrants, including, without limitation, representing the appropriate number of
shares of the Successor Entity, having similar exercise rights as the Warrants (including but not
limited to a similar Exercise Price and similar Exercise Price adjustment provisions based on the
price per share or conversion ratio to be received by the holders of Common Stock in the Major
Transaction) and similar registration rights as provided by the Registration Rights Agreement ,
satisfactory to the Holder and (ii) any Successor Entity (including its Parent Entity) is a
publicly traded corporation whose common stock is quoted on or listed for trading on an Eligible
Market. Upon the occurrence of any Major Transaction, any Successor Entity shall succeed to, and be
substituted for (so that from and after the date of such Major Transaction, the provisions of this
Warrant and the Registration Rights Agreement referring to the “Company” shall refer instead to the
Successor Entity), and may exercise every right and power of the Company and shall assume all of
the obligations of the Company under this Warrant with the same effect as if such Successor Entity
had been named as the

 

 

Company herein. Upon consummation of the Major Transaction, the Successor Entity shall deliver to
the Holder confirmation that there shall be issued upon exercise or redemption of this Warrant at
any time after the consummation of the Major Transaction, in lieu of the shares of Common Stock (or
other securities, cash, assets or other property) issuable upon the exercise of the Warrants prior
to such Major Transaction, such shares of publicly traded common stock (or their equivalent) of the
Successor Entity, as adjusted in accordance with the provisions of this Warrant. The provisions of
this Section shall apply similarly and equally to successive Major Transactions and shall be
applied without regard to any limitations on the exercise of this Warrant other than any applicable
beneficial ownership limitations. Any assumption of Company obligations under this paragraph shall
be referred to herein as an “Assumption”.

(iii) Notice; Major Transaction Redemption Right. At least thirty (30) days prior to the
consummation of any Major Transaction, but, in any event, on the first to occur of (x) the date of
the public announcement of such Major Transaction if such announcement is made before 4:00 p.m.,
New York City time, or (y) the day following the public announcement of such Major Transaction if
such announcement is made on and after 4:00 p.m., New York City time, the Company shall deliver
written notice thereof via facsimile and overnight courier to the Holder (a “Major Transaction
Notice”). At any time during the period beginning after the Holder’s receipt of a Major Transaction
Notice and ending five (5) Trading Days prior to the consummation of such Major Transaction, the
Holder may require the Company to redeem (a “Redemption Upon Major Transaction”) all or any portion
of this Warrant by delivering written notice thereof (“Major Transaction Redemption Notice”) to the
Company, which Major Transaction Redemption Notice shall indicate the portion of the Warrant that
the Holder is electing to have redeemed (the “Redeemed Amount”). The Redeemed Amount shall be
redeemed in cash at a price (the “Major Transaction Warrant Redemption Price”) equal to the Black
Scholes value determined in accordance with Section 10(b) hereof of the Redeemed Amount;
provided, however, that in the event that the Major Transaction does not provide
for or involve the payment of cash consideration in an aggregate amount that is at least equal to
the Major Transaction Warrant Redemption Price for the Redeemed Amount, all cash consideration
shall be applied to the redemption of a percentage of such Redeemed Amount equal to a fraction the
numerator of which is such cash consideration and the denominator of which is the full Black
Scholes value (determined in accordance with Section 10(b) hereof) of the entire Redeemed Amount,
and provided, further, no cash or debt instruments relating to a Major Transaction
shall be retained by the Company or distributed or received by security holders of the Company
unless the entire Redeemed Amount is so redeemed for cash. Notwithstanding anything herein to the
contrary, in the event that the entire Redeemed Amount is not so redeemed, the Holder shall have
the right to treat the portion of the Warrant that is not redeemed by virtue of the shortfall as an
Assumption under Section 5(c)(ii).

(iv) Escrow; Payment of Major Transaction Warrant Redemption Price. Following the receipt of a
Major Transaction Redemption Notice from the Holder, the Company shall not consummate a Major
Transaction unless it (or in the case of a Major Transaction resulting in proceeds to the Company
consisting solely of cash consideration, the counterparty to such transaction) shall first place
into an escrow account with an independent escrow agent, at least three (3) business days prior to
the closing date of the Major Transaction (the “Major Transaction Escrow Deadline”), an amount in
cash equal to the Major Transaction Warrant Redemption Price. Concurrently upon closing of any
Major Transaction, the Company shall pay or shall instruct the escrow agent to pay the Major
Transaction Warrant Redemption Price to the Holder. For purposes of determining the amount
required to be placed in escrow pursuant to the provisions of this subsection (iv) and without
affecting the amount of the actual Major Transaction Warrant Redemption Price, the calculation of
the price referred to in clause (1) of the first column of Schedule 1 hereto with respect to Stock
Price shall be determined based on the Closing Market Price (as defined herein) of the Common Stock
on the Trading Day immediately preceding the date that the funds are deposited with the escrow
agent.

(v) Injunction. Following the receipt of a Major Transaction Redemption Notice from the Holder, in
the event that the Company attempts to consummate a Major Transaction without placing the Major
Transaction Warrant Redemption Price in escrow in accordance with subsection (iv) above or without
payment of the Major Transaction Warrant Redemption Price to the Holder upon consummation of such
Major Transaction, the Holder shall have the right to apply for an injunction in any state or
federal courts sitting in the City of New York, borough of Manhattan to prevent the closing of such
Major Transaction until the Major Transaction Redemption Price is paid to the Holder, in full.

Redemptions required by this Section 5(c) shall be made in accordance with the provisions of
Section 12 and shall have priority to payments to holders of Common Stock in connection with a
Major Transaction. To the extent redemptions required by this Section 5(c)(iii) are deemed or
determined by a court of competent jurisdiction to be prepayments of the Warrant by the Company,
such redemptions shall be deemed to be voluntary prepayments. Notwithstanding anything to the
contrary in this Section 5, until the Major Transaction Redemption Price is paid in full, this
Warrant may be exercised, in whole or in part, by the Holder into shares of Common Stock, or in the
event the Exercise Date is after the consummation of the Major Transaction, shares of publicly
traded common stock (or their equivalent) of the Successor Entity pursuant to Section 5(c). The
parties hereto agree that in the event of the Company’s redemption of any portion of the Warrant
under this Section 5(c), the Holder’s damages would be uncertain and difficult to estimate because
of the parties’ inability to predict future interest rates and the uncertainty of the availability
of a suitable substitute investment opportunity for the Holder. Accordingly, any redemption premium
due under this Section 5(c) is intended by the parties to be, and shall be deemed, a reasonable
estimate of the Holder’s actual loss of its investment opportunity and not as a penalty.

For purposes hereof:

“Eligible Market” means the over the counter Bulletin Board, the New York Stock Exchange, Inc., the
NYSE Arca, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market or
the American Stock Exchange.

 

 

“Parent Entity” of a Person means an entity that, directly or indirectly, controls the applicable
Person and whose common stock or equivalent equity security is quoted or listed on an Eligible
Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity
with the largest public market capitalization as of the date of consummation of a Major
Transaction.

“Person” means an individual, a limited liability company, a partnership, a joint venture, a
corporation, a trust, an unincorporated organization, any other entity and a government or any
department or agency thereof.

(d) Exercise Price Adjusted. As used in this Warrant, the term “Exercise Price” shall mean the
purchase price per share specified in Section 3 of this Warrant, until the occurrence of an event
stated in this Section 5 or otherwise set forth in this Warrant, and thereafter shall mean said
price as adjusted from time to time in accordance with the provisions of said subsection. No such
adjustment under this Section 5 shall be made unless such adjustment would change the Exercise
Price at the time by $.01 or more; provided, however, that all adjustments not so made shall be
deferred and made when the aggregate thereof would change the Exercise Price at the time by $.01 or
more. No adjustment made pursuant to any provision of this Section 5 shall have the net effect of
increasing the Exercise Price in relation to the split adjusted and distribution adjusted price of
the Common Stock.

(e) Adjustments: Additional Shares, Securities or Assets. In the event that at any time, as a
result of an adjustment made pursuant to this Section 5 or otherwise, Holder shall, upon Exercise
of this Warrant, become entitled to receive shares and/or other securities or assets (other than
Common Stock) then, wherever appropriate, all references herein to shares of Common Stock shall be
deemed to refer to and include such shares and/or other securities or assets; and thereafter the
number of such shares and/or other securities or assets shall be subject to adjustment from time to
time in a manner and upon terms as nearly equivalent as practicable to the provisions of this
Section 5.

(f) Adjustment of Exercise Price upon Issuance of Common Stock, Options, Convertible Securities,
Etc. (i) If at any time after the Date of Issuance for so long as any Warrants are outstanding,
the Company (A) issues or sells any Common Stock, Convertible Securities, warrants, or Options or
(B) directly or indirectly effectively reduces the conversion, exercise or exchange price for any
Convertible Securities or Options which are currently outstanding, at or to an effective Per Share
Selling Price (as defined below) which is less than the greater of (I) the closing sale price per
share of the Common Stock on the Eligible Market which the Common Stock is traded on the Trading
Day immediately preceding such issue or sale (“Fair Market Price”), or (II) the Exercise Price,
then in each such case the Exercise Price in effect immediately prior to such issue or sale date,
as applicable, shall be automatically reduced effective concurrently with such issue or sale to an
amount determined by multiplying the Exercise Price then in effect by a fraction, (x) the numerator
of which shall be the sum of (1) the number of shares of Common Stock outstanding immediately prior
to such issue or sale, plus (2) the number of shares of Common Stock which the aggregate
consideration received by the Company for such additional shares would purchase at such Fair Market
Price or Exercise Price, as the case may be, and (y) the denominator of which shall be the number
of shares of Common Stock of the Company outstanding immediately after such issue or sale. The
foregoing provision shall not apply to any issuances or sales of Common Stock or Convertible
Securities (i) pursuant to any Convertible Securities or Options currently outstanding on the date
hereof in accordance with the terms of such Convertible Securities in effect on the date hereof
provided that such securities have not been amended since the date hereof to directly or indirectly
effectively reduce the conversion, exercise or exchange price for any Convertible Securities or
Options which are currently outstanding, or (ii) any Common Stock issued or issuable upon exercise
of any options to employees, officers, directors, consultants and advisors (and any individuals who
have accepted an offer of employment), in each case in connection with any Approved Stock Plan (as
defined below), up to a maximum amount of Common Stock not to exceed in any one calendar year
commencing on the Date of Issuance of 5% of the total number of outstanding shares of the Company
not held by affiliates of the Company as of the beginning of such calendar year.

For the purposes of the foregoing adjustments, in the case of the issuance of any Convertible
Securities or Options, the maximum number of shares of Common Stock issuable upon exercise,
exchange or conversion of such Convertible Securities or Options shall be deemed to be outstanding,
provided that no further adjustment shall be made upon the actual issuance of Common Stock upon
exercise, exchange or conversion of such Convertible Securities or Options, and provided further
that to the extent such Convertible Securities or Options expire or terminate unconverted or
unexercised, then at such time the Exercise Price shall be readjusted as if such portion of such
Convertible Securities or Options had not been issued.

For purposes of this Section 5(f), if an event occurs that triggers more than one of the above
adjustment provisions, then only one adjustment shall be made and the calculation method which
yields the greatest downward adjustment in the Exercise Price shall be used.

For purposes of determining the adjusted Exercise Price under this Section 5(f), the following
shall be applicable:

(ii) Record Date. If the Company takes a record of the holders of Common Stock for the purpose of
entitling them (1) to receive a dividend or other distribution payable in Common Stock, Options or
in Convertible Securities or (2) to subscribe for or purchase Common Stock, Options or Convertible
Securities, then such record date will be deemed to be the date of the issue or sale of the Common
Stock deemed to have been issued or sold upon the declaration of such dividend or the making of
such other distribution or the date of the granting of such right of subscription or purchase, as
the case may be.

 

 

(iii) Other Events. If any event occurs of the type contemplated by the provisions of this Section
5(f) but not expressly provided for by such provisions (including, without limitation, the granting
of stock appreciation rights, phantom stock rights or other rights with equity features), then the
Company’s Board of Directors will make such adjustment in the Exercise Price as it in its
discretion deems appropriate so as to protect the rights of the Holder under this Warrant; provided
that no such adjustment will increase the Exercise Price as otherwise determined pursuant to this
Section 5(f).

For purposes hereof:

“Approved Stock Plan” means any employee benefit plan which has been duly adopted by a majority of
the non-employee members of the Board of Directors of the Company or a majority of the members of a
committee of non-employee directors established for such purpose, pursuant to which the Company’s
securities may be issued to any employee, consultant, advisor, officer or director (or any
individual who has accepted an offer of employment) for services provided to the Company, and in
all cases, providing for an Exercise Price that is at or above the Volume Weighted Average Price on
the date of the grant.

“Convertible Securities” means any stock or securities (other than Options) directly or indirectly
convertible into or exercisable or exchangeable for Common Stock.

“Options” means any rights, warrants or options to subscribe for or purchase Common Stock or
Convertible Securities.

“Per Share Selling Price” shall include the amount actually paid by third parties for each share of
Common Stock in a sale or issuance by the Company. In the event a fee is paid by the Company in
connection with such transaction directly or indirectly to such third party or its affiliates, any
such fee shall be deducted from the selling price pro rata to all shares sold in the transaction to
arrive at the Per Share Selling Price. A sale of shares of Common Stock shall include the sale or
issuance of Convertible Securities or Options, and in such circumstances the Per Share Selling
Price of the Common Stock covered thereby shall also include the exercise, exchange or conversion
price thereof (in addition to the consideration received by the Company upon such sale or issuance
less the fee amount as provided above). In case of any such security issued in a transaction in
which the purchase price or the conversion, exchange or exercise price is directly or indirectly
subject to adjustment or reset based on a future date, future trading prices of the Common Stock,
specified or contingent events directly or indirectly related to the business of the Company or the
market for the Common Stock, or otherwise (but excluding standard stock split anti-dilution
provisions or weighted-average anti-dilution provisions similar to that set forth herein, provided
that any actual reduction of such price under any such security pursuant to such weighted-average
anti-dilution provision shall be included and cause an adjustment hereunder), the Per Share Selling
Price shall be deemed to be the lowest conversion, exchange, exercise or reset price at which such
securities are converted, exchanged, exercised or reset or might have been converted, exchanged,
exercised or reset, or the lowest adjustment, as the case may be, over the life of such securities.
If shares are issued for a consideration other than cash, the Per Share Selling Price shall be the
fair value of such consideration as determined in good faith by independent certified public
accountants mutually acceptable to the Company and the Holder. In the event the Company directly
or indirectly effectively reduces the conversion, exercise or exchange price for any Convertible
Securities or Options which are currently outstanding, then the Per Share Selling Price shall equal
such effectively reduced conversion, exercise or exchange price.

(g) Subsequent Rights Offerings. If the Company, at anytime prior to the date that all of the
Warrants have been Exercised, redeemed or otherwise satisfied in accordance with their terms, shall
issue rights, options or warrants to all holders of Common Stock (and not to Holders) entitling
them to subscribe for or purchase shares of Common Stock at a price per share (the “Base Rights
Offering Price”) that is lower than the Volume Weighted Average Price on the record date referenced
below, then the Exercise Price then in effect shall be reduced to the Base Rights Offering Price.
Such adjustment shall be made whenever such rights or warrants are issued, and shall become
effective immediately after the record date for the determination of stockholders entitled to
receive such rights, options or warrants. No adjustment shall be made hereunder if such adjustment
would result in an increase of the Exercise Price then in effect.

(h) Notice of Adjustments. Whenever the Exercise Price is adjusted pursuant to the terms of this
Warrant, the Company shall promptly mail to the Holder a notice (an “Exercise Price Adjustment
Notice”) setting forth the Exercise Price after such adjustment and setting forth a statement of
the facts requiring such adjustment. The Company shall, upon the written request at any time of the
Holder, furnish to such Holder a like Warrant setting forth (i) such adjustment or readjustment,
(ii) the Exercise Price at the time in effect and (iii) the number of shares of Common Stock and
the amount, if any, of other securities or property which at the time would be received upon
Exercise of the Warrant. For purposes of clarification, whether or not the Company provides an
Exercise Price Adjustment Notice pursuant to this Section 5(h), upon the occurrence of any event
that leads to an adjustment of the Exercise Price, the Holders are entitled to receive a number of
Exercise Shares based upon the new Exercise Price, as adjusted, for exercises occurring on or after
the date of such adjustment, regardless of whether a Holder accurately refers to the adjusted
Exercise Price in the Exercise Form.

(i) Purchase Rights. In addition to any other adjustments described herein, if at any time the
Company grants, issues or sells any Options, Convertible Securities or rights to purchase stock,
warrants, securities or other property pro rata to the record holders of any class of shares of
Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have
acquired if the Holder had held the proportionate number of shares of Common Stock acquirable upon
complete exercise of this Warrant (without regard to any limitations on the exercise of this
Warrant) immediately before the date on which a record is taken for the grant, issuance or sale of
such Purchase

 

 

Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights.

6. Fractional Interests.

No fractional shares or scrip representing fractional shares shall be issuable upon the Exercise of
this Warrant, but on Exercise of this Warrant, Holder may purchase only a whole number of shares of
Common Stock. If, on Exercise of this Warrant, Holder would be entitled to a fractional share of
Common Stock or a right to acquire a fractional share of Common Stock, such fractional share shall
be disregarded and the number of shares of Common Stock issuable upon Exercise shall be the next
higher number of shares.

7. Reservation of Shares.

From and after the date hereof, the Company shall at all times reserve for issuance such number of
authorized and unissued shares of Common Stock (or other securities substituted therefor as herein
above provided) as shall be sufficient for the Exercise of this Warrant and payment of the Exercise
Price. If at any time the number of shares of Common Stock authorized and reserved for issuance is
below the number of shares sufficient for the Exercise of this Warrant (a “Share Authorization
Failure”) (based on the Exercise Price in effect from time to time), the Company will promptly take
all corporate action necessary to authorize and reserve a sufficient number of shares, including,
without limitation, calling a special meeting of stockholders to authorize additional shares to
meet the Company’s obligations under this Section 7, in the case of an insufficient number of
authorized shares, and using its best efforts to obtain stockholder approval of an increase in such
authorized number of shares. The Company covenants and agrees that upon the Exercise of this
Warrant, all shares of Common Stock issuable upon such Exercise shall be duly and validly issued,
fully paid and nonassessable and not subject to preemptive rights, rights of first refusal or
similar rights of any person or entity.

8. Restrictions on Transfer.

(a) Registration or Exemption Required. This Warrant has been issued in a transaction exempt from
the registration requirements of the Securities Act by virtue of Regulation D and exempt from state
registration under applicable state laws. The Warrant and the Common Stock issuable upon the
Exercise of this Warrant may not be pledged, transferred, sold or assigned except pursuant to an
effective registration statement or an exemption to the registration requirements of the Securities
Act and applicable state laws including, without limitation, a so-called “4(1) and a half”
transaction.

(b) Assignment. Subject to Section 8(a), the Holder may sell, transfer, assign, pledge or otherwise
dispose of this Warrant, in whole or in part. Holder shall deliver a written notice to Company,
substantially in the form of the Assignment attached hereto as Exhibit B, indicating the
person or persons to whom the Warrant shall be assigned and the respective number of warrants to be
assigned to each assignee. The Company shall effect the assignment within three (3) business days
(the “Transfer Delivery Period”), and shall deliver to the assignee(s) designated by Holder a
Warrant or Warrants of like tenor and terms for the appropriate number of shares. This Warrant and
the rights evidenced hereby shall inure to the benefit of and be binding upon the successors and
assigns of the Holder. The provisions of this Warrant are intended to be for the benefit of all
Holders from time to time of this Warrant, and shall be enforceable by any such Holder. For
avoidance of doubt, in the event Holder notifies the Company that such sale or transfer is a so
called “4(1) and half” transaction, the parties hereto agree that a legal opinion from outside
counsel for the Holder delivered to counsel for the Company substantially in the form attached
hereto as Exhibit C shall be the only requirement to satisfy an exemption from registration under
the Securities Act to effectuate such “4(1) and half” transaction.

9. Noncircumvention. The Company hereby covenants and agrees that the Company will not, by
amendment of its certificate of incorporation, bylaws or through any reorganization, transfer of
assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, and will at all times in good faith carry out all the provisions of this
Warrant and take all action as may be required to protect the rights of the Holder. Without
limiting the generality of the foregoing, the Company (i) shall not increase the par value of any
shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then
in effect, and (ii) shall take all such actions as may be necessary or appropriate in order that
the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon
the exercise of this Warrant.

10. Events of Failure; Definition of Black Scholes Value.

(a) Definition.

The occurrence of each of the following shall be considered to be an “Event of Failure.”

(i) A Delivery Failure occurs, where a “Delivery Failure” shall be deemed to have
occurred if the Company fails to use its best efforts to deliver Exercise Shares to
the Holder within any applicable Delivery Period;

(ii) A Legend Removal Failure occurs, where a “Legend Removal Failure” shall be
deemed to have occurred if the Company fails to use its best efforts to issue this
Warrant and/or Exercise Shares without a restrictive legend, or fails to use its best
efforts to remove a restrictive legend, when and as required under Section 2(e)
hereof;

 

 

(iii) a Transfer Delivery Failure occurs, where a “Transfer Delivery Failure” shall
be deemed to have occurred if the Company fails to use its best efforts to deliver a
Warrant within any applicable Transfer Delivery Period; and

(iv) a Registration Failure (as defined below).

For purpose hereof, “Registration Failure” means that (A) the Company fails to file with the SEC on
or before the Filing Deadline (as defined in the Registration Rights Agreement) any Registration
Statement required to be filed pursuant to Section 2(a) of the Registration Rights Agreement, or
(B) the Company fails to use its best efforts to obtain effectiveness with the SEC, prior to the
Registration Deadline (as defined in the Registration Rights Agreement), and, if such Registration
Statement is not so filed prior to the Registration Deadline, as soon as possible thereafter, of
any Registration Statement (as defined in the Registration Rights Agreement) that are required to
be filed pursuant to Section 2(a) of the Registration Rights Agreement, or fails to use best
efforts to keep such Registration Statement current and effective as required in Section 3 of the
Registration Rights Agreement, (C) the Company fails to file any amendment to the Registration
Statement, or any additional Registration Statement required to be filed pursuant to Section 3(b)
of the Registration Rights Agreement within twenty (20) days of the applicable Registration Trigger
Date (as defined in the Registration Rights Agreement), or fails to use its best efforts to cause
such amendment and/or new Registration Statement to become effective within sixty (60) days of the
applicable Registration Trigger Date, and, if such effectiveness does not occur within such period,
as soon as possible thereafter, or (iv) any Registration Statement required to be filed under the
Registration Rights Agreement, after its initial effectiveness and during the Registration Period
(as defined in the Registration Rights Agreement), lapses in effect or sales of all of the
Registrable Securities (as defined in the Registration Rights Agreement) cannot otherwise be made
thereunder (whether by reason of the Company’s failure to amend or supplement the prospectus
included therein in accordance with the Registration Rights Agreement, the Company’s failure to
file and use best efforts to obtain effectiveness with the SEC of an additional Registration
Statement or amended Registration Statement required pursuant to Section 3 of the Registration
Rights Agreement or otherwise), or (D) the Company fails to provide a commercially reasonable
written response to any comments to any Registration Statement submitted by the SEC within ten (10)
days of the date that such SEC comments are received by the Company.

(b) Failure Payments; Black-Scholes Determination. The Company understands that any Event of
Failure (as defined above) could result in economic loss to the Holder. In the event that any Event
of Failure occurs, as compensation to the Holder for such loss, the Company agrees to pay (as
liquidated damages and not as a penalty) to the Holder payments (“Failure Payments”) at a rate of
18% per annum (or the maximum rate permitted by applicable law, whichever is less) of the
Black-Scholes value (as determined below) of the remaining unexercised portion of this Warrant on
the date of such request (as recalculated on the first business day of each month thereafter for as
long as Failure Payments shall continue to accrue), which shall accrue daily from the date of such
Event of Failure until the Event of Failure is cured, accruing daily and compounded monthly. For
purposes of clarification, it is agreed and understood that Failure Payments shall continue to
accrue following any Event of Default until the applicable Default Amount is paid in full.

For purposes hereof, the “Black-Scholes” value of a Warrant shall be determined by use of the Black
Scholes Option Pricing Model using the criteria set forth on Schedule 1 hereto.

(c) Payment of Accrued Failure Payments. The accrued Failure Payments for each Event of Failure
shall be paid in immediately available funds on or before the fifth (5th) day of each month
following a month in which Failure Payments accrued. Nothing herein shall limit the Holder’s right
to pursue actual damages (to the extent in excess of the Failure Payments) for the Company’s Event
of Failure, and the Holder shall have the right to pursue all remedies available at law or in
equity (including a decree of specific performance and/or injunctive relief). Notwithstanding the
above, if a particular Event of Failure results in an Event of Default pursuant to Section 11
hereof, then the Failure Payment, for that Event of Failure only, shall be considered to have been
satisfied upon payment to the Holder of an amount equal to the greater of (i) the Failure Payment,
or (ii) the Default Amount, payable in accordance with Section 11.

(d) Maximum Interest Rate. Nothing contained herein or in any document referred to herein or
delivered in connection herewith shall be deemed to establish or require the payment of a rate of
interest or other charges in excess of the maximum permitted by applicable law. In the event that
the rate of interest or dividends required to be paid or other charges hereunder exceed the maximum
permitted by such law, any payments in excess of such maximum shall be credited against amounts
owed by the Company to the Holder and thus refunded to the Company.

11. Default and Redemption.

(a) Events Of Default. Each of the following events shall be considered to be an “Event of
Default,” unless waived by the Holder:

(i) Failure To Effect Registration. A Registration Failure occurs and remains uncured for a period
of more than thirty (30) days;

(ii) Failure To Deliver Common Stock. A Delivery Failure (as defined above) occurs and remains
uncured for a period of more than twenty (20) days; or at any time, the Company announces or states
in writing that it will not honor its obligations to issue shares of Common Stock to the Holder
upon Exercise by the Holder of the Exercise rights of the Holder in accordance with the terms of
this Warrant.

(iii) Legend Removal Failure. A Legend Removal Failure (as defined above) occurs and remains
uncured for a period of twenty (20) days; and

 

 

(iv) Corporate Existence; Major Transaction. The Company has effected a Major Transaction without
paying the Major Transaction Warrant Redemption Price to the Holder pursuant to Section 5(c)(iii)
or, if the Holder did not elect a Redemption Upon Major Transaction, the Company has failed to meet
the Assumption requirements of Section 5(c)(iii) prior to effecting a Major Transaction.

(b) Mandatory Redemption.

(i) Mandatory Redemption Amount. If any Events of Default shall occur then, unless waived by the
Holder, upon the occurrence and during the continuation of any Event of Default, at the option of
the Holder, such option exercisable through the delivery of written notice to the Company by such
Holder (the “Default Notice”), the outstanding amount of this Warrant shall be immediately redeemed
by the Company and the Company shall pay to the Holder (a “Mandatory Redemption”), in full
satisfaction of its obligations hereunder, an amount (the “Mandatory Redemption Amount” or the
“Default Amount”) equal to the greater of (i) the Black-Scholes value (as determined in accordance
with Section 10(b)) of the remaining unexercised portion of this Warrant on the date of such
Default Notice and (2) the Black-Scholes value (also as determined in accordance with Section
10(b)) of the remaining unexercised portion of this Warrant on the Trading Day immediately
preceding the date that the Mandatory Redemption Amount is paid to the Holder.

The Mandatory Redemption Amount shall be payable, in cash or cash equivalent, within five (5)
business days of the Date of the applicable Default Notice.

(ii) Liquidated Damages. The parties hereto acknowledge and agree that the sums payable as Failure
Payments or pursuant to a Mandatory Redemption shall give rise to liquidated damages and not
penalties. The parties further acknowledge that (i) the amount of loss or damages likely to be
incurred by the Holder is incapable or is difficult to precisely estimate, (ii) the amounts
specified bear a reasonable proportion and are not plainly or grossly disproportionate to the
probable loss likely to be incurred by the Holder, and (iii) the parties are sophisticated business
parties and have been represented by sophisticated and able legal and financial counsel and
negotiated this Agreement at arm’s length.

The Default Amount, together with all other amounts payable hereunder, shall immediately become due
and payable, all without demand, presentment or notice, all of which hereby are expressly waived,
together with all costs, including, without limitation, legal fees and expenses, of collection, and
the Holder shall be entitled to exercise all other rights and remedies available at law or in
equity.

(c) Remedies, Other Obligations, Breaches And Injunctive Relief. The remedies provided in this
Warrant shall be cumulative and in addition to all other remedies available under this Warrant, the
Purchase Agreement and the Registration Rights Agreement, at law or in equity (including a decree
of specific performance and/or other injunctive relief), and nothing herein shall limit the right
of the Holder to pursue actual damages for any failure by the Company to comply with the terms of
this Warrant. The Company acknowledges that a breach by it of its obligations hereunder will cause
irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate.
The Company therefore agrees that, in the event of any such breach or threatened breach, the holder
of this Warrant shall be entitled, in addition to all other available remedies, to an injunction
restraining any breach, without the necessity of showing economic loss and without any bond or
other security being required.

Section 12. Holder’s Redemptions.

(a) Mechanics of Holder’s Redemptions. In the event that the Holder has sent a Default Notice or a
Major Transaction Redemption Notice to the Company pursuant to Section 5(c) or a Default Notice
pursuant to Section 11(b)(i), respectively (each, a “Redemption Notice”), the Holder shall promptly
submit this Warrant to the Company. If the Holder has submitted a Major Transaction Redemption
Notice in accordance with Section 5(c)(iii), the Company shall deliver the applicable Major
Transaction Redemption Price to the Holder concurrently with the consummation of such Major
Transaction. In the event that the Company does not pay the applicable Major Transaction Warrant
Redemption Price to the Holder within the time period required, at any time thereafter and until
the Company pays such unpaid Major Transaction Warrant Redemption Price in full, the Holder shall
have the option, in lieu of redemption, to require the Company to promptly return to the Holder all
or any portion of this Warrant that was submitted for redemption and for which the applicable Major
Transaction Warrant Redemption Price (together with any late charges thereon) has not been paid.
Upon the Company’s receipt of such notice, (x) the applicable Redemption Notice shall be null and
void with respect to such Redemption Principal Amount, (y) the Company shall immediately return
this Warrant, or issue a new Warrant to the Holder representing the portion of this Warrant that
was submitted for redemption and (z) the Exercise Price of this Warrant or such new Warrant shall
be adjusted to the lesser of (A) the Exercise Price as in effect on the date on which the
applicable Redemption Notice is voided and (B) the lowest Closing Price during the period beginning
on and including the date on which the applicable Redemption Notice is delivered to the Company and
ending on and including the date on which the applicable Redemption Notice is voided. The Holder’s
delivery of a notice voiding a Redemption Notice and exercise of its rights following such notice
shall not affect the Company’s obligations to make any payments of Failure Payments which have
accrued prior to the date of such notice with respect to the Warrant subject to such notice.

13. Benefits of this Warrant.

Nothing in this Warrant shall be construed to confer upon any person other than the Company and
Holder any legal or equitable right, remedy or claim under this Warrant and this Warrant shall be
for the sole and exclusive benefit of the Company and Holder.

 

 

14. Governing Law.

All questions concerning the construction, validity, enforcement and interpretation of this
Agreement shall be governed by and construed and enforced in accordance with the internal laws of
the State of New York, without regard to the principles of conflicts of law thereof. Each party
agrees that all legal proceedings concerning the interpretations, enforcement and defense of the
transactions contemplated by this Agreement (whether brought against a party hereto or its
respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby
irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the
City of New York, borough of Manhattan for the adjudication of any dispute hereunder or in
connection herewith or with any transaction contemplated hereby or discussed herein, and hereby
irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it
is not personally subject to the jurisdiction of any such court, that such suit, action or
proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby
irrevocably waives personal service of process and consents to process being served in any such
suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve
process in any other manner permitted by law. The parties hereby waive all rights to a trial by
jury. If either party shall commence an action or proceeding to enforce any provisions of this
Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other
party for its reasonable attorneys’ fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such action or proceeding.

15. Loss of Warrant.

Upon receipt by the Company of evidence of the loss, theft, destruction or mutilation of this
Warrant, and (in the case of loss, theft or destruction) of indemnity or security reasonably
satisfactory to the Company, and upon surrender and cancellation of this Warrant, if mutilated, the
Company shall execute and deliver a new Warrant of like tenor and date.

16. Notice or Demands.

Notices or demands pursuant to this Warrant to be given or made by Holder to or on the Company
shall be sufficiently given or made if sent by certified or registered mail, return receipt
requested, postage prepaid, and addressed, until another address is designated in writing by the
Company, to the address set forth in Section 2(a) above. Notices or demands pursuant to this
Warrant to be given or made by the Company to or on Holder shall be sufficiently given or made if
sent by certified or registered mail, return receipt requested, postage prepaid, and addressed, to
the address of Holder set forth in the Company’s records, until another address is designated in
writing by Holder.

 

 

IN WITNESS WHEREOF, the undersigned has executed this Warrant as of the ___day of November, 2007.

	 	 	 	 	 
	MIDDLEBROOK PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 
	By:
	 	 	 	 
	 
	Print Name:

	 	 
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}]]